warnings
WARNINGS Azelastine hydrochloride ophthalmic solution, 0.05% is for topical ophthalmic use only and not for injection or oral use.
Azelastine Hydrochloride
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Azelastine Hydrochloride
- Generic name
- AZELASTINE HYDROCHLORIDE
- Manufacturer
- Sandoz Inc
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 6945fb86-27fb-4bab-8908-98772c6269c5
- SPL ID
- 50b267f7-5553-45a4-a409-2d53417c5b39
- Version
- 5
- Effective date
- 2025-12-11
- Source export date
- 2026-11-06
- Source partition
- 8
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0008-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-06/db89d5ebfc3e02f44e8769334d799cd3436b05f779823ab00297f1f800c89ddf/drug-label-0008-of-0014.json.zip
- Source manifest SHA-256
- 4a7570ba105b5a039a8e1c94a85e7f085b9047a8882a35a96bf1e4516c5ffc97
- Import run
- 20261108T063105Z
- Imported at
- 2026-11-08 07:37:23
| Harmonized routes |
|---|
| INTRAOCULAR |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | ANDA | 202305 | derived:openfda.application_number |
| application number | ANDA202305 | openfda.application_number | |
| brand name | Azelastine Hydrochloride | openfda.brand_name | |
| generic name | AZELASTINE HYDROCHLORIDE | openfda.generic_name | |
| manufacturer name | Sandoz Inc | openfda.manufacturer_name | |
| ndc | package | 61314-308-02 | openfda.package_ndc |
| ndc | product | 61314-308 | openfda.product_ndc |
| ndc11 | package | 61314030802 | derived:openfda.package_ndc |
| rxcui | 860805 | openfda.rxcui | |
| spl id | 50b267f7-5553-45a4-a409-2d53417c5b39 | id | |
| spl set id | 6945fb86-27fb-4bab-8908-98772c6269c5 | set_id | |
| unii | 0L591QR10I | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS In controlled multiple-dose studies where patients were treated for up to 56 days, the most frequently reported adverse reactions were transient eye burning/stinging (approximately 30%), headaches (approximately 15%) and bitter taste (approximately 10%). The occurrence of these events was generally mild. The following events were reported in 1–10% of patients: asthma, conjunctivitis, dyspnea, eye pain, fatigue, influenza-like symptoms, pharyngitis, pruritus, rhinitis and temporary blurring. Some of these events were similar to the underlying disease being studied.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.